Home/Filings/4/0001193125-26-002248
4//SEC Filing

Bruno Lawrence 4

Accession 0001193125-26-002248

CIK 0001958086other

Filed

Jan 4, 7:00 PM ET

Accepted

Jan 5, 3:16 PM ET

Size

8.4 KB

Accession

0001193125-26-002248

Insider Transaction Report

Form 4
Period: 2025-12-31
Bruno Lawrence
DirectorChairman and CEO
Transactions
  • Tax Payment

    Common Stock

    2025-12-31$16.03/sh112,681$1,806,276257,438 total
  • Exercise/Conversion

    Common Stock

    2025-12-31+180,722370,119 total
  • Exercise/Conversion

    Performance Shares

    2025-12-31180,7220 total
    Exercise: $0.00Common Stock (180,722 underlying)
Footnotes (1)
  • [F1]These shares were awarded as restricted performance shares in February 2023, as disclosed in the Reporting Person's Form 4 filing on February 21, 2023. The Company finished in the 68th percentile of return on invested capital among the Bloomberg Peer Group at the conclusion of the performance period on December 31, 2025. Therefore, the performance criteria and requirements for vesting have been satisfied at 116.5% of the target award level, and such number of shares vested on December 31, 2025.

Documents

1 file

Issuer

Core Laboratories Inc. /DE/

CIK 0001958086

Entity typeother

Related Parties

1
  • filerCIK 0001730336

Filing Metadata

Form type
4
Filed
Jan 4, 7:00 PM ET
Accepted
Jan 5, 3:16 PM ET
Size
8.4 KB